Li Yan Wang1, Deven T Hamilton2, Eli S Rosenberg3, Maria V Aslam4, Patrick S Sullivan5, David A Katz6, Richard L Dunville7, Lisa C Barrios7, Steven M Goodreau8. 1. Division of Adolescent and School Health, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: lgw0@cdc.gov. 2. Center for Studies in Demography and Ecology, University of Washington, Seattle, Washington. 3. Department of Epidemiology and Biostatistics, University at Albany School of Public Health, State University of New York, Rensselaer, New York. 4. Office of the Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. 5. Department of Epidemiology, Emory University, Atlanta, Georgia; Department of Global Health, Emory University, Atlanta, Georgia. 6. Department of Global Health, University of Washington, Seattle, Washington. 7. Division of Adolescent and School Health, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. 8. Center for Studies in Demography and Ecology, University of Washington, Seattle, Washington; Department of Anthropology, University of Washington, Seattle, Washington.
Abstract
PURPOSE: Pre-exposure prophylaxis (PrEP) has been proven safe and effective in preventing HIV among adolescent sexual minority males (ASMM), but the cost-effectiveness of PrEP in ASMM remains unknown. Building on a recent epidemiological network modeling study of PrEP among ASMM, we estimated the cost-effectiveness of PrEP use in a high prevalence U.S. setting with significant disparities in HIV between black and white ASMM. METHODS: Based on the estimated number of infections averted and the number of ASMM on PrEP from the previous model and published estimates of PrEP costs, HIV treatment costs, and quality-adjusted life years (QALYs) gained per infection prevented, we estimated the cost-effectiveness of PrEP use in black and white ASMM over 10 years using a societal perspective and lifetime horizon. Effectiveness was measured as lifetime QALYs gained. Cost estimates included 10-year PrEP costs and lifetime HIV treatment costs saved. Cost-effectiveness was measured as cost/QALY gained. Multiple sensitivity analyses were performed on key model input parameters and assumptions used. RESULTS: Under base-case assumptions, PrEP use yielded an incremental cost-effectiveness ratio of $33,064 per QALY in black ASMM and $427,788 per QALY in white ASMM. In all sensitivity analyses, the cost-effectiveness ratio of PrEP use remained <$100,000 per QALY in black ASMM and >$100,000 per QALY in white ASMM. CONCLUSIONS: We found favorable cost-effectiveness ratios for PrEP use among black ASMM or other ASMM in communities with high HIV burden at current PrEP costs. Clinicians providing services in high-prevalence communities, and particularly those serving high-prevalence communities of color, should consider including PrEP services. Published by Elsevier Inc.
PURPOSE: Pre-exposure prophylaxis (PrEP) has been proven safe and effective in preventing HIV among adolescent sexual minority males (ASMM), but the cost-effectiveness of PrEP in ASMM remains unknown. Building on a recent epidemiological network modeling study of PrEP among ASMM, we estimated the cost-effectiveness of PrEP use in a high prevalence U.S. setting with significant disparities in HIV between black and white ASMM. METHODS: Based on the estimated number of infections averted and the number of ASMM on PrEP from the previous model and published estimates of PrEP costs, HIV treatment costs, and quality-adjusted life years (QALYs) gained per infection prevented, we estimated the cost-effectiveness of PrEP use in black and white ASMM over 10 years using a societal perspective and lifetime horizon. Effectiveness was measured as lifetime QALYs gained. Cost estimates included 10-year PrEP costs and lifetime HIV treatment costs saved. Cost-effectiveness was measured as cost/QALY gained. Multiple sensitivity analyses were performed on key model input parameters and assumptions used. RESULTS: Under base-case assumptions, PrEP use yielded an incremental cost-effectiveness ratio of $33,064 per QALY in black ASMM and $427,788 per QALY in white ASMM. In all sensitivity analyses, the cost-effectiveness ratio of PrEP use remained <$100,000 per QALY in black ASMM and >$100,000 per QALY in white ASMM. CONCLUSIONS: We found favorable cost-effectiveness ratios for PrEP use among black ASMM or other ASMM in communities with high HIV burden at current PrEP costs. Clinicians providing services in high-prevalence communities, and particularly those serving high-prevalence communities of color, should consider including PrEP services. Published by Elsevier Inc.
Entities:
Keywords:
Adolescent sexual minority males; Cost-effectiveness; PrEP use
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Sybil G Hosek; Bret Rudy; Raphael Landovitz; Bill Kapogiannis; George Siberry; Brandy Rutledge; Nancy Liu; Jennifer Brothers; Kathleen Mulligan; Gregory Zimet; Michelle Lally; Kenneth H Mayer; Peter Anderson; Jennifer Kiser; James F Rooney; Craig M Wilson Journal: J Acquir Immune Defic Syndr Date: 2017-01-01 Impact factor: 3.731
Authors: Deven T Hamilton; Steven M Goodreau; Samuel M Jenness; Patrick S Sullivan; Li Yan Wang; Richard L Dunville; Lisa C Barrios; Eli S Rosenberg Journal: Am J Public Health Date: 2018-11 Impact factor: 9.308
Authors: Steven M Goodreau; Eli S Rosenberg; Samuel M Jenness; Nicole Luisi; Sarah E Stansfield; Gregorio A Millett; Patrick S Sullivan Journal: Lancet HIV Date: 2017-04-18 Impact factor: 12.767
Authors: Laura Kann; Tim McManus; William A Harris; Shari L Shanklin; Katherine H Flint; Barbara Queen; Richard Lowry; David Chyen; Lisa Whittle; Jemekia Thornton; Connie Lim; Denise Bradford; Yoshimi Yamakawa; Michelle Leon; Nancy Brener; Kathleen A Ethier Journal: MMWR Surveill Summ Date: 2018-06-15
Authors: Steven M Goodreau; Deven T Hamilton; Samuel M Jenness; Patrick S Sullivan; Rachel K Valencia; Li Yan Wang; Richard L Dunville; Lisa C Barrios; Eli S Rosenberg Journal: J Adolesc Health Date: 2017-12-13 Impact factor: 5.012
Authors: Angela B Hutchinson; Pragna Patel; Stephanie L Sansom; Paul G Farnham; Timothy J Sullivan; Berry Bennett; Peter R Kerndt; Robert K Bolan; James D Heffelfinger; Vimalanand S Prabhu; Bernard M Branson Journal: PLoS Med Date: 2010-09-28 Impact factor: 11.069
Authors: Deven T Hamilton; Eli S Rosenberg; Patrick S Sullivan; Li Yan Wang; Richard L Dunville; Lisa C Barrios; Maria Aslam; Brian Mustanski; Steven M Goodreau Journal: J Adolesc Health Date: 2020-08-11 Impact factor: 5.012
Authors: David A Katz; Deven T Hamilton; Elizabeth M Rosenthal; Li Yan Wang; Richard L Dunville; Maria Aslam; Lisa C Barrios; Maria Zlotorzynska; Travis H Sanchez; Patrick S Sullivan; Eli S Rosenberg; Steven M Goodreau Journal: Sex Transm Dis Date: 2021-12-01 Impact factor: 2.830